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Abstract
Previous	 studies	 have	 shown	 sex‐related	 differences	 in	 the	 incidence	 of	 adverse	
events	following	treatment	with	fluoropyrimidines,	however	the	mechanism	of	this	
difference	is	unknown.	We	examined	sex‐related	differences	in	the	safety	of	S‐1	plus	
oxaliplatin	(SOX)	and	S‐1	plus	cisplatin	(CS)	in	663	metastatic	gastric	cancer	patients	
taking	part	 in	a	phase	 III	 study.	The	 incidences	of	 leukopenia	 (odds	ratio	 [OR]	1.9;	
P = .015),	neutropenia	(OR	2.2;	P = .002),	nausea	(OR	2.0;	P = .009),	and	vomiting	(OR	
2.8; P < .001)	were	increased	in	women	versus	men	treated	with	SOX,	while	vomiting	
(OR	2.9;	P < .001)	and	stomatitis	(OR	1.8;	P = .043)	were	increased	in	women	versus	
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1  | INTRODUC TION
Gastric	 cancer	 is	 the	 3rd	 leading	 cause	 of	 cancer‐related	 deaths	
worldwide.1	Fluoropyrimidines	have	been	used	as	key	drugs	for	pa‐
tients	with	metastatic	gastric	cancer	for	more	than	half	a	century.	It	is	
known	that	female	patients	treated	with	fluoropyrimidines	develop	
leukopenia,	stomatitis,	diarrhea,	nausea,	vomiting,	and	alopecia	more	
often	 and	more	 severely	 than	male	patients.2‐6	Dose	modification	
and	the	administration	schedule	of	5‐fluorouracil	(5‐FU),	a	fluoropy‐
rimidine,	and	optimum	supportive	therapies	for	female	patients	are	
not	under	current	consideration	and	are	not	implemented	in	clinical	
practice,	even	though	sex‐related	differences	in	adverse	reactions	to	
fluoropyrimidines	have	been	previously	 reported.	Lower	clearance	
of	 5‐FU,	 could	 reduce	 the	 activity	 of	 dihydropyrimidine	 dehydro‐
genase	(DPD),	which	is	the	initial	enzyme	in	catabolism	of	5‐FU.2,7 
Polymorphisms	in	DPD	or	thymidylate	synthase5,8	are	thought	to	be	
possible	causes	of	sex‐related	differences	in	adverse	events	follow‐
ing	fluoropyrimidine	treatment,	although	the	fundamental	cause	of	
this	perceived	difference	is	not	yet	known.	Furthermore,	a	previous	
investigation	into	DPD	expression	and	activity	in	the	human	liver	did	
not	reveal	any	sex‐related	differences.5
Sex‐related	differences	in	the	toxicity	of	anticancer	agents	have	
not	 only	 been	observed	 for	5‐FU	 treatment,	 but	 also	 for	 cisplatin	
and	adriamycin,	and	in	other	anticancer	agents.9	Female	patients	had	
significantly	higher	rates	of	vomiting	and	nausea,	however	the	cause	
of	 this	 sex‐related	difference	 is	 also	unknown.10	Conversely,	 body	
mass	index	was	inversely	correlated	with	a	decrease	in	platelet	count	
following	cisplatin	and	etoposide	treatment,	whereas	there	was	no	
significant	effect	of	sex	on	this	related	parameter.11
S‐1	is	an	oral	combination	preparation	consisting	of	tegafur,	a	pro‐
drug	of	5‐FU,	and	the	modulators	gimeracil	and	oteracil	potassium.	
Gimeracil	prevents	the	degradation	of	5‐FU	by	reversibly	inhibiting	
DPD	which	is	the	primary	metabolizing	enzyme	of	fluorouracil,	and	
oteracil	potassium	inhibits	the	activity	of	5‐FU	in	the	gastrointestinal	
tissue	and	decreases	gastrointestinal	toxicity.12	In	patients	with	com‐
promised	renal	function,	gimeracil	clearance	is	decreased,	leading	to	
high	 concentrations	of	 5‐FU	 in	 the	blood	 and	 an	 increased	 risk	 of	
5‐FU‐related	side	effects.13	We	examined	the	incidence	of	diarrhea	
in	metastatic	colorectal	cancer	patients	treated	with	S‐1	plus	oxal‐
iplatin	(SOX)	and	plus	bevacizumab,	according	to	renal	function	in	the	
previous	SOFT	trial.14	The	incidence	of	grade	3,	or	higher,	diarrhea	
among	patients	with	a	creatinine	clearance	rate	(CCr)	of	<70	mL/min	
before	treatment	exceeded	20%	and	tended	to	be	higher	than	the	
incidence	among	patients	with	a	CCr	of	≥70	mL/min.	Another	study,	
G‐SOX,	compared	treatment	with	SOX	and	treatment	with	S‐1	plus	
cisplatin	 (CS)	and	demonstrated	comparable	 results	 for	both	 treat‐
ments	in	progression‐free	survival	(PFS)	and	overall	survival	(OS).15 In 
this	study,	we	aimed	to	evaluate	and	compare	the	safety	and	efficacy	
of	the	SOX	and	CS	therapies	in	female	and	male	patients	with	meta‐
static	gastric	cancer.
2  | MATERIAL S AND METHODS
2.1 | Patients
The	G‐SOX	 trial	 was	 a	 randomized,	 open‐label,	 phase	 III	 study	
that	compared	the	efficacy	and	safety	of	the	SOX	and	CS	treat‐
ment	 regimens	 in	 patients	 with	 curatively	 unresectable,	 ad‐
vanced,	 or	 recurrent	 gastric	 cancer.15	 In	 total,	 685	 randomized	
patients	were	studied	and	data	collected	from	January	2010	until	
October	2011.	The	SOX	regimen	was	confirmed	to	be	non‐infe‐
rior	to	the	CS	regimen.	In	the	SOX	regimen,	S‐1	was	given	orally	
for	 the	1st	2	wk	of	a	3‐wk	cycle,	and	oxaliplatin	was	 infused	at	
100	mg/m2	on	day	1.	In	the	CS	regimen,	S‐1	was	given	for	the	1st	
3	wk	of	a	5‐wk	cycle,	and	cisplatin	was	administered	at	60	mg/m2 
on	day	8.	The	CCr	was	estimated	using	the	Cockcroft‐Gault	equa‐
tion.	The	proportion	of	female	patients	treated	with	SOX	and	CS	
was	24.0%	(81/338)	and	27.5%	(92/335)	in	the	safety	analysis	set	
(SAF),	and	24.3%	(81/333)	and	27.3%	(90/330)	in	the	full	analysis	
set	(FAS),	respectively.
2.2 | Statistical analysis
Median	OS	and	PFS	were	estimated	using	the	Kaplan‐Meier	method.	
Differences	in	therapeutic	efficacy	between	SOX	and	CS	were	tested	
using	the	log‐rank	test.	Statistical	significance	was	considered	to	be	
men	treated	with	CS.	In	contrast,	male	patients	treated	with	CS	experienced	throm‐
bocytopenia	more	often	(OR	0.51;	P = .009).	The	mean	relative	dose	intensity	of	S‐1	
in	SOX	was	75.4%	in	women	and	81.4%	in	men	(P = .032).	No	difference	in	efficacy	
was	observed	between	women	and	men	undergoing	either	regimen.	Sex‐related	dif‐
ferences	in	adverse	reactions	during	SOX	and	CS	treatment	were	confirmed	in	this	
phase	 III	 study.	Further	 translational	 research	studies	are	warranted	 to	pursue	 the	
cause	of	this	difference.
K E Y W O R D S
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at	a	value	of	P < .05.	The	Cox	proportional	hazards	model	was	used	
to	estimate	hazard	ratios	(HRs)	of	SOX	compared	with	CS	with	95%	
confidence	intervals	(CIs).	Efficacy	was	analyzed	in	the	FAS,	which	
included	patients	who	met	 the	main	 inclusion	criteria	and	none	of	
the	exclusion	criteria	in	the	SAF.
The	 incidence	 of	 adverse	 events	 in	 female	 or	 male	 patients	
during	the	1st	treatment	cycle	was	compared	between	the	two	reg‐
imens	using	Fisher's	exact	test	and	logistic	regression.	Multivariate	
analyses	for	toxicities	were	also	carried	out	using	a	logistic	regres‐
sion	model.	Adverse	events	were	assessed	 in	accordance	with	the	
Common	 Terminology	 Criteria	 for	 Adverse	 Events	 version	 3.0.	
Furthermore,	treatment	delivery	was	evaluated	for	both	women	and	
men	in	both	treatment	groups.	Statistical	analyses	were	performed	
using	SAS	version	9.3	software	(SAS	Institute).
3  | RESULTS
Baseline	characteristics	of	all	patients	enrolled	in	the	G‐SOX	study	
were	comparable	between	the	two	sexes	and	treatment	groups.	The	
numbers	of	histologically	undifferentiated	type	gastric	cancer	were	
higher	in	women	than	in	men	(Table	1).
3.1 | Safety
Adverse	events	are	listed	in	Table	2.	The	median	CCrs	of	female	
patients	 in	 the	SOX	group	and	the	CS	group	were	72.9	mL/min	
(range,	36.5‐137.7	mL/min)	and	76.8	mL/min	(41.7‐211.0	mL/min),	
and	 those	 of	male	 patients	were	 75.8	mL/min	 (33.7‐189.2	mL/
TA B L E  1  Baseline	characteristics	in	male	and	female	patients
SOX
P a 
CS
P a Male (n = 257) Female (n = 81) Male (n = 243) Female (n = 92)
n % n % n % n %
Age
	<65 111 43.2 42 51.9 .201 109 44.9 53 57.6 .038
	≥65 146 56.8 39 48.1 134 55.1 39 42.4
ECOG	performance	status
 0 183 71.2 56 63.5 .414 177 72.8 59 64.1 .109
 1 72 28.0 23 28.4 62 25.5 33 35.9
 2 2 0.8 2 2.5 4 1.6 0 0
Unresectable 207 80.5 71 87.7 .182 199 81.9 78 84.8 .628
Recurrent 50 19.5 10 12.3 44 18.1 14 15.2
	Adjuvant	chemotherapy	(+) 24 9.3 7 8.6 20 8.2 9 9.8
	Adjuvant	chemotherapy	(‐) 26 10.1 3 3.7 24 9.9 5 5.4
Tumor	histology
	Differentiated	type 125 48.6 29 35.8 .055 119 49.0 29 31.5 .005
	Undifferentiated	type 132 51.4 52 64.2 124 51.0 63 68.5
Primary	tumor
	‐ 66 25.7 13 16.0 .097 62 25.5 17 18.5 .196
	+ 191 74.3 68 84.0 181 74.5 75 81.5
No.	of	metastatic	sites
 1 87 33.9 22 27.2 .377 78 32.1 26 28.3 .455
 2 105 40.9 33 40.7 107 44.0 36 39.1
	≥3 59 23.0 24 29.6 57 23.5 27 29.3
Metastatic	site	b 
	Liver 104 40.5 22 27.2 101 41.6 30 32.6
	Lung 32 12.5 5 6.2 27 11.1 8 8.7
	Lymph	node 225 87.5 74 91.4 214 88.1 79 85.9
	Peritoneum 45 17.5 21 25.9 44 18.1 21 22.8
Abbreviations:	CS,	cisplatin	plus	S‐1;	ECOG,	Eastern	Cooperative	Oncology	Group;	SOX,	S‐1	plus	oxaliplatin.
aFisher's	exact	test;	comparing	proportion	of	each	characteristic.
bPatients	can	be	included	in	more	than	one	category.
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min)	and	79.4	mL/min	(41.1‐151.2	mL/min),	respectively.	Female	
patients	 treated	 with	 SOX	 developed	 leukopenia,	 neutropenia,	
nausea,	 and	 vomiting	 significantly	 more	 frequently	 than	 male	
patients,	while	women	 treated	with	CS	 demonstrated	 vomiting	
and	stomatitis	in	the	1st	treatment	cycle	more	often,	regardless	
of	 renal	 function,	 as	 compared	with	men.	 In	 contrast,	male	 pa‐
tients	undergoing	CS	therapy	experienced	thrombocytopenia	in	
the	1st	cycle	more	often	compared	with	female	patients.	Sex	was	
TA B L E  3  Multivariate	analyses	for	adverse	events	during	the	first	cycle	of	treatment	with	S‐1	plus	oxaliplatin	and	S‐1	plus	cisplatin
 Leukopenia Neutropenia Thrombocytopenia Nausea Vomiting Diarrhea Stomatitis
S‐1	plus	oxaliplatin
	Sex,	female	vs	male
	OR,	95%	CI 1.9,	1.1‐3.3 2.2,	1.3‐3.7 0.70,	0.39‐1.32 2.0,	1.2‐3.3 2.8,	1.6‐4.9 1.3,	0.78‐2.3 0.73,	0.28‐1.9
 P‐value .015 .0036 .25 .0096 .0004 .30 .51
	CCr,	70	mL/min≤	vs	70	mL/min>
	OR,	95%	CI 0.78,	0.43‐1.4 0.55,	0.31‐0.97 0.82,	0.43‐1.5 0.94,	0.55‐1.6 0.68,	0.35‐1.3 0.56,	0.32‐1.0 0.52,	0.20‐1.3
 P‐value .41 .039 .53 .83 .25 .053 .17
	BMI,	median≤	vs	median	>	per	sex
	OR,	95%	CI 0.72,	0.43‐1.2 0.81,	0.50‐1.3 1.2,	0.67‐2.0 0.76,	0.48‐1.2 0.85,	0.48‐1.5 1.3,	0.78‐2.1 1.2,	0.55‐2.8
 P‐value .20 .40 .61 .26 .59 .33 .60
	Age,	70≤	vs	70>
	OR,	95%	CI 0.91,	0.50‐1.6 0.63,	0.36‐1.1 0.64,	0.34‐1.2 1.1,	0.63‐1.9 0.77,	0.40‐1.5 0.95,	0.53‐1.7 1.0,	0.41‐2.6
 P‐value .75 .12 .18 .79 .45 .86 .93
	PS,	1,	or	2	vs	0
	OR,	95%	CI 0.90,	0.53‐1.5 0.60,	0.36‐1.0 0.92,	0.53‐1.6 0.92,	0.57‐1.5 1.8,	1.0‐3.1 1.1,	0.63‐1.8 2.0,	0.90‐4.3
 P‐value .69 .057 .78 .75 .040 .84 .088
	Peritoneal	dissemination,	yes	vs	no
	OR,	95%	CI 0.97,	0.53‐1.8 1.1,	0.62‐1.9 1.1,	0.58‐2.1 1.3,	0.74‐2.3 0.80,	0.40‐1.6 1.3,	0.75‐2.4 1.4,	0.56‐3.5
 P‐value .92 .75 .78 .36 .52 .32 .47
	S‐1	plus	cisplatin
	Sex,	female	vs	male
	OR,	95%	CI 0.98,	0.60‐1.6 0.66,	0.40‐1.1 0.52,	0.31‐0.88 1.4,	0.86‐2.3 2.8,	1.7‐4.9 1.5,	0.87‐2.4 1.9,	1.1‐3.4
 P‐value .94 .11 .014 .17 .0001 .15 .022
	CCr,	70	mL/min≤	vs	70	mL/min>
	OR,	95%	CI 0.59,	0.36‐0.99 0.60,	0.35‐1.0 0.78,	0.47‐1.3 0.74,	0.44‐1.2 0.55,	0.31‐0.98 0.91,	0.54‐1.6 0.94,	0.52‐1.7
 P‐value .044 .06 .35 .25 .042 .74 .84
	BMI,	median≤	vs	median	>	per	sex
	OR,	95%	CI 0.67,	0.42‐1.1 0.53,	0.33‐0.85 0.83,	0.52‐1.3 1.2,	0.76‐1.9 0.85,	0.49‐1.5 0.68,	0.42‐1.1 0.77,	0.44‐1.3
 P‐value 0.086 0.0084 0.43 0.44 0.55 0.12 0.34
	Age,	≤70	vs	>70	years
	OR,	95%	CI 1.3,	0.77‐2.2 0.98,	0.57‐1.7 1.9,	1.1‐3.2 0.84,	0.51‐1.4 1.1,	0.59‐1.9 1.2,	0.72‐2.1 1.8,	1.0‐3.2
 P‐value .33 .94 .016 .51 .85 .46 .045
	PS,	1,	or	2	vs	0
	OR,	95%	CI 1.0,	0.60‐1.6 1.5,	0.87‐2.4 0.89,	0.54‐1.5 1.1,	0.67‐1.8 1.1,	0.60‐1.9 1.4,	0.84‐2.3 1.3,	0.74‐2.3
 P‐value .91 .15 .64 .71 .86 .20 .36
	Peritoneal	dissemination,	yes	vs	no
	OR,	95%	CI 1.6,	0.91‐2.8 0.93,	0.53‐1.7 1.0,	0.59‐1.8 1.5,	0.85‐2.6 1.2,	0.65‐2.3 0.76,	0.42‐1.4 0.82,	0.41‐1.6
 P‐value .11 .81 .91 .16 .54 .38 .56
The	median	BMI	of	female	patients	treated	with	S‐1	plus	oxaliplatin	or	S‐1	plus	cisplatin	were	20.4	kg/m2,	and	the	BMI	of	males	were	21.6	kg/m2.
Abbreviations:	BMI,	body	mass	index;	CCr,	creatinine	clearance;	CI,	confidence	interval;	OR,	odds	ratio;	PS,	performance	status.
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an	 independent	 predictive	marker	 of	 those	 toxicities	 (Table	 3).	
Thrombocytopenia	 following	 CS	 treatment	 was	 also	 observed	
more	frequently	in	patients	aged	70	years	or	older	as	measured	
by	multivariate	analysis.
The	incidences	of	nausea	and	vomiting	were	higher	in	women,	even	
though	aprepitant	was	not	commonly	administered	to	patients	treated	
with	SOX.	Aprepitant	was	given	to	9.3%	of	male	patients	and	11.1%	
of	female	patients	in	the	SOX	group,	and	74.5%	of	male	patients	and	
73.9%	of	female	patients	in	the	CS	group.	Despite	aprepitant	admin‐
istration,	all	grades	of	vomiting	were	still	observed.	Although	the	inci‐
dence	of	vomiting	decreased	to	22%	(2/9)	for	women	and	17%	(4/24)	
for	men,	there	was	no	difference	in	the	incidence	of	vomiting	between	
women	 and	men	 (P = 1.0).	The	 incidence	of	vomiting	 (39%;	 28/72)	
in	women	was	 significantly	 higher	 than	 that	 in	men	 (18%;	 41/233)	
(P = .0003)	in	the	SOX	group	when	aprepitant	was	not	given	(Table	4).	
The	mean	relative	dose	intensities	(RDIs)	for	S‐1	during	the	three	cy‐
cles	of	SOX	were	 significantly	 lower	 in	women	 (75.4%)	 than	 that	 in	
men	(81.4%)	(P = .032),	while	the	RDIs	for	S‐1	during	the	two	cycles	of	
CS	were	84.0%	in	women	and	79.6%	in	men	(P = .081)	(Table	5).	The	
reasons	 for	 the	dose	reduction	of	oxaliplatin	did	not	differ	between	
female	patients	or	male	patients	treated	with	SOX	(Table	6).
3.2 | Efficacy
In	female	patients,	the	median	OS	was	14.4	mo	for	SOX	and	12.6	mo	
for	CS	 (HR	0.812,	 95%	CI	 0.577‐1.143;	P = .233)	 (Figure	 1),	while	
the	median	PFS	was	5.5	mo	for	SOX	and	4.1	mo	for	CS	(HR	0.877,	
95%	CI	0.621‐1.237;	P = .454)	 (Figure	2).	 In	 the	male	patients,	 the	
median	OS	was	14.3	mo	for	SOX	and	14.2	mo	for	CS	(HR	0.976,	95%	
CI	0.800‐1.190;	P = .808)	(Figure	1),	while	median	PFS	was	5.4	mo	
for	SOX	and	5.5	mo	for	CS	(HR	0.952,	95%	CI	0.778‐1.165;	P = .633)	
(Figure	2).	The	response	rates	were	49.4%	(95%	CI	38.1‐60.7)	in	fe‐
male	patients	and	54.8%	(95%	CI	48.4‐61.0)	in	male	patients	for	SOX	
(P = .443),	and	46.7%	(95%	CI	36.1‐57.5)	in	female	patients	and	52.9%	
(95%	CI	46.4‐59.4)	in	male	patients	for	CS	(P = .325).	No	significant	
differences	 in	 efficacy	with	 regard	 to	OS,	 PFS,	 and	 response	 rate	
were	identified	between	the	sexes	in	either	treatment	group.
4  | DISCUSSION
Leukopenia,	neutropenia,	nausea,	and	vomiting	during	the	1st	cycle	
of	SOX	treatment,	and	vomiting	and	stomatitis	during	the	1st	cycle	
of	CS	treatment	were	more	frequently	observed	in	female	patients	
compared	with	male	patients.	In	contrast,	thrombocytopenia	devel‐
oped	more	often	 in	male	patients	compared	with	 female	patients.	
However,	no	significant	sex‐related	difference	was	observed	in	the	
incidence	of	subjective	adverse	reactions	such	as	diarrhea	because	
patients	could	themselves	temporarily	stop	oral	S‐1	by	assessing	ad‐
equate	self‐administration,	in	contrast	with	infused	5‐FU.	There	was	
also	no	difference	in	the	incidence	of	leukopenia	and	neutropenia	in	
patients	 treated	with	CS.	The	pharmacokinetics	of	5‐FU	after	oral	
S‐1	administration	could	vary	 in	patients	because	cisplatin	can	 im‐
pair	 renal	 function	 and	 decrease	 5‐FU	 clearance.	 This	 decrease	 is	
through	reduced	clearance	of	gimeracil,	a	DPD	inhibitor,	that	leads	
to	high	concentrations	of	5‐FU	in	the	blood.	Therefore,	the	effect	of	
cisplatin	treatment	on	sex‐related	differences	 in	adverse	reactions	
induced	 by	 5‐FU	 would	 be	 more	 variable	 compared	 with	 oxalipl‐
atin	 treatment.	Despite	 the	observed	differences	between	 female	
patients	and	male	patients	of	 these	 toxicities,	 their	cause	was	not	
clearly	explained	from	this	study	on	its	own.
5‐Fluorouracil	 clearance	 is	 significantly	 lower	 in	 women	
than	 in	men	regardless	of	patient	age	and	the	given	5‐FU	dose.2 
Plasma	 samples	 from	 the	 1st	 cycle	 of	 391	 female	 patients	 and	
536	male	 patients	 treated	with	 a	 2400	mg/m2	 continuous	 infu‐
sion	of	5‐FU	over	44‐48	h	were	tested	for	5‐FU.	These	analyses	
indicated	that,	when	comparing	the	proposed	optimal	area	under	
the	plasma	drug	concentration‐time	curve	 (AUC)	 target	 range	of	
20‐30	 mg	 h/L,	 women	 received	 supraoptimal	 doses	 compared	
with	 men	 (P = .0083).16	 This	 higher	 plasma	 5‐FU	 concentration	
was	significantly	related	to	severer	neutropenia	and	stomatitis.17 
More	than	80%	of	a	given	dose	of	5‐FU	is	rapidly	catabolized	to	
dihydrofluorouracil	 by	DPD,	 the	 rate‐limiting	 enzyme	 of	 pyrimi‐
dine	metabolism,	and	to	 inactive	dihydrouracil.7	Toxicity	 from	5‐
FU	 in	women	was	 found	 in	a	 recent	 study	 to	be	 independent	of	
DPYD	 genotype.	 Female	 patients	 had	 a	 two‐fold	 higher	 risk	 for	
severe	 5‐FU‐related	 toxicity	 compared	 with	 male	 patients	 and	
toxicity	 in	women	was	 independent	 of	DPYD	 genotype	 because	
the	OR	 for	 toxicity	 of	 41.8	 (95%	CI,	 9.2‐190,	P < .0001)	 in	men	
with	DPYD	polymorphism	was	much	higher	 than	 the	OR	of	1.33	
(95%	CI,	0.34‐5.2,	P = .68)	in	women.	In	addition,	analysis	from	the	
same	study	of	DPD	expression	and	activity	in	the	human	liver	did	
not	 reveal	 any	 sex‐related	differences.	Evidence	 for	methylation	
of	 the	DPYD	 promotor	 in	 the	 same	DNA	 from	 the	 same	 human	
liver	was	not	found.5	Pretherapeutic	dihydrouracil	concentration	
was	significantly	higher	in	female	colorectal	cancer	patients	com‐
pared	with	male	 patients,	 however	 the	dihydrouracil/uracil	 ratio	
did	 not	 differ	 according	 to	 sex.	 A	 high	 level	 of	 uracil	 in	 females	
TA B L E  4  The	incidence	of	any	grade	of	nausea	and	vomiting	by	
S‐1	plus	oxaliplatin	(SOX)	and	S‐1	plus	cisplatin	(CS)
Arm
Aprepitant 
(1st cycle)
Female Male Fisher
n % n % P
Nausea
	SOX No 41 57 94 40 .015
Yes 5 56 9 38 .44
	CS No 14 58 32 52 .64
Yes 41 60 91 50 .20
Vomiting
	SOX No 28 39 41 18 .0003
Yes 2 22 4 17 1.0
	CS No 13 54 15 24 .011
Yes 25 37 33 18 .0038
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might	 therefore	be	associated	with	hematologic	 toxicity	after	5‐
FU‐based	chemotherapy.
Another	recent	study	has	shown	that	global	capecitabine	tox‐
icities	were	associated	with	rare,	functional	DPYD	alleles	2846T>A	
(minor	allele	frequency,	0.6%)	and	*2A	(IVS14	+	1G>A,	0.4%)	(com‐
bined	 OR,	 5.51;	 P = .0013),	 the	 common	 TYMS	 polymorphism	
5′VNTR2R/3R	 (47%),	 and	 a	 3′UTR	 6‐bp	 Indel	 (31%)	 (combined	
OR,	1.31;	P = 9.4 × 10−6).8	The	higher	 incidence	of	5‐FU‐related	
toxicities	 is	 difficult	 to	 explain	 by	 these	 rare	 DPYD	 variants.	 In	
total,	3‐5%	of	Caucasians	have	reduced	DPD	activity,18 however 
DPYD	 variants	 in	 the	 Japanese	 population	 are	 somewhat	 differ‐
ent	from	the	previously	reported	Caucasian	variants.	DPYD alleles 
2303C>A	and	103G>T	might	play	important	roles	in	5‐FU‐related	
toxicity	 for	 Japanese	patients.19	The	sensitivity	of	DPYD	 genetic	
testing	depends	on	the	number	of	variants	investigated.	By	com‐
bining	the	DPYD	variants	c.1905	+	1G>A	(also	known	as	DPYD *	2A,	
IVS14	 +	 1G>A),	 c.2846A>T,	 c.1679T>G,	 c.1129‐5923C>G,	 the	
20%‐30%	 rate	of	 early‐onset	5‐fluorouracil	 toxicities	 can	be	 ex‐
plained.20,21	 Patients	 without	 a	 DPYD	 decreased/no	 function	
variant	may	still	experience	severe	toxicity	due	to	other	genetic,	
environmental,	or	other	factors.21
Tegafur	 is	 converted	 to	 5‐FU	 mainly	 by	 CYP2A6,	 and	 poly‐
morphisms	 in	 CYP2A6	 are	 thought	 to	 be	 related	 to	 5‐FU	 toxic‐
ity.22	 In	 addition,	 previous	 studies	 have	 suggested	 that	CYP2A6	
activity	is	higher	in	women	and	could	be	induced	by	estradiol	via	
ERα,	although	further	studies	are	required	to	confirm	this	sugges‐
tion.23	 Sex	differences	are	well	 known	 in	disease	manifestations	
and	 treatment	 effects	 such	 as	 in	 autoimmune	 or	 cardiovascular	
diseases,	 and	 reaction	 to	vaccines.	Despite	 these	 insights,	 the	X	
chromosome	 is	 scrutinized	 less	 often	 in	 the	 current	 era	 of	 pop‐
ulation	 genetics	 analyses	 due	 to	 unique	 statistical	 challenges,24 
although	 genome	 analyses	 of	 sex	 chromosomes	 could	 resolve	
some	 profound	 medical	 questions	 such	 as	 described	 here.	 The	
reason	for	the	higher	incidence	of	thrombocytopenia	in	male	pa‐
tients	 treated	with	CS	 therapy	 could	 not	 be	 clearly	 understood.	
Thrombocytopenia	 after	 CS	was	 not	 correlated	with	 body	mass	
index,	this	result	differed	from	that	of	a	previous	study	on	cispla‐
tin‐based	therapy.11
In	 our	 study,	 no	 statistically	 significant	 relationship	 between	
treatment	effects	and	sex	was	observed,	although	the	incidence	of	
adverse	events	was	higher	in	female	patients	who	more	commonly	
have	undifferentiated	type	adenocarcinoma	with	a	worse	prognosis	
compared	with	the	differentiated	type.	Intensive	antiemetic	therapy	
TA B L E  5  Total	dose	and	relative	dose	intensity
 
SOX
P
CS
P
Male Female Male Female
(n = 221) (n = 73) (n = 221) (n = 81)
S‐1
	RDI	(%) Median 83.7 75.0 .029a 83.3 83.3 .411a
 [Range] [17.0‐114.5] [13.0‐100]  [2.4‐112.9] [11.9‐101.7]  
 Mean,	SD 81.4,	20.6 75.4,	21.6 .032b 79.6,	22.7 84.0,	18.0 .081b
Oxaliplatin/cisplatin
	RDI	(%) Median 98.3 75.0 .077a 87.5 87.5 .958a
 [Range] [0‐100] [28.0‐100]  [0‐134.6] [0‐102.9]  
 Mean,	SD 83.5,	20.0 79.1,	20.0 .100b 80.3,	30.2 82.1,	27.2 .636b
SOX	for	3	cycles,	CS	for	2	cycles.
Abbreviations:	CS;	S‐1	plus	cisplatin,	RDI,	relative	dose	intensity;	SD,	standard	deviation;	SOX,	S‐1	plus	oxaliplatin.
aWilcoxon	rank	sum	test.	
bt‐test.	
TA B L E  6  Reasons	for	dose	reduction	of	oxaliplatin	in	S‐1	plus	
oxaliplatin	(SOX)
Dose reduction of oxaliplatina
Male Female
(n = 257) (n = 81)
n % n %
Thrombocytopenia:	≥75	000/
mm3	(≤Grade	1)	is	not	met	by	
day 29
40 15.6 12 14.8
Thrombocytopenia:	<25	000/
mm3	(Grade	4)
2 0.8 0 0
Thrombocytopenia:	platelet	
transfusion	was	performed
1 0.4 0 0
Neutropenia:	<500/mm3 
(Grade	4)
1 0.4 1 1.2
Febrile	neutropenia:	neu‐
trophil	count	<	1000/
mm3	and	fever	(axillary	
temperature)	≥	38.0°C
0 0 1 1.2
Diarrhea:	≥Grade	3 10 3.9 4 4.9
Stomatitis:	≥Grade	3 1 0.4 0 0
Sensory	neuropathy	(Grade	2) 33 12.8 7 8.6
Investigator's	judgment 59 23.0 23 28.4
aPatients	can	be	included	in	more	than	one	category.	
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with	 aprepitant	 should	 be	 considered	 because	 of	 the	 higher	 inci‐
dence	of	nausea	and	vomiting	in	SOX	and	vomiting	in	CS.	It	is	difficult	
to	reduce	the	starting	dose	of	SOX	for	female	patients	due	to	their	
higher	incidence	of	adverse	events	compared	with	male	patients	and	
because	severe	toxicities	were	rarely	induced	by	SOX	with	100	mg/
m2	of	oxaliplatin.15	Conversely,	the	oxaliplatin	dose	should	rather	be	
increased	to	the	recommended	dose	of	130	mg/m2,	as	proposed	by	
the	phase	I/II	 trial	on	SOX,25	along	with	full	supportive	antiemetic	
therapy	 for	male	patients.	 In	 conclusion,	 incidences	of	 sex‐related	
differences	in	adverse	reactions	during	treatment	with	SOX	and	CS	
were	confirmed	in	the	G‐SOX	study.	Further	fundamental	research	
studies	are	warranted	to	pursue	the	underlying	cause.
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F I G U R E  1  Overall	survival	(OS)	
according	to	sex	and	treatment	arms.	
Checkmarks	represent	censored	patients.	
CS,	S‐1	plus	cisplatin;	FAS,	full	analysis	
set;	SOX,	S‐1	plus	oxaliplatin.
F I G U R E  2  Progression‐free	survival	
according	to	sex	and	treatment	arms.	
Checkmarks	represent	censored	patients.	
CS,	S‐1	plus	cisplatin;	FAS,	full	analysis	
set;	SOX,	S‐1	plus	oxaliplatin.
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